IN2012DN00167A - - Google Patents

Info

Publication number
IN2012DN00167A
IN2012DN00167A IN167DEN2012A IN2012DN00167A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A IN 167DEN2012 A IN167DEN2012 A IN 167DEN2012A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A
Authority
IN
India
Prior art keywords
treatment
compositions
concerned
methods
multiple sclerosis
Prior art date
Application number
Other languages
English (en)
Inventor
B Gelder Frank
Alison Webster Gillian
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of IN2012DN00167A publication Critical patent/IN2012DN00167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
IN167DEN2012 2009-06-16 2010-06-16 IN2012DN00167A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (fr) 2009-06-16 2010-06-16 Compositions et procédés pour le traitement de la sclérose en plaques

Publications (1)

Publication Number Publication Date
IN2012DN00167A true IN2012DN00167A (fr) 2015-04-17

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
IN167DEN2012 IN2012DN00167A (fr) 2009-06-16 2010-06-16

Country Status (20)

Country Link
US (1) US8389479B2 (fr)
EP (1) EP2442832B1 (fr)
JP (1) JP5646617B2 (fr)
CN (1) CN102458476B (fr)
AU (1) AU2010260585B2 (fr)
BR (1) BRPI1009606A2 (fr)
CA (1) CA2688766C (fr)
CY (1) CY1115714T1 (fr)
DK (1) DK2442832T3 (fr)
ES (1) ES2521565T3 (fr)
HR (1) HRP20141035T1 (fr)
IL (1) IL216993A (fr)
IN (1) IN2012DN00167A (fr)
MX (1) MX2011013661A (fr)
NZ (1) NZ577731A (fr)
PL (1) PL2442832T3 (fr)
PT (1) PT2442832E (fr)
SI (1) SI2442832T1 (fr)
SM (1) SMT201400165B (fr)
WO (1) WO2010147484A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009123480A1 (fr) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Agents anti-infectieux et utilisations de ces derniers
WO2012061074A1 (fr) * 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. Procédés de détermination de différences dans l'activité alpha-4 intégrine par la corrélation de différences des taux de svcam et/ou de smadcam
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
AU2016202146A1 (en) * 2015-10-06 2017-04-20 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (fr) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions et méthodes de traitement de l'épilepsie
WO2017070731A1 (fr) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions et méthodes pour le traitement de la maladie d'alzheimer
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
EP3793583A4 (fr) * 2018-05-18 2022-03-09 Université Laval Utilisation d'un agoniste de nod2 pour le traitement, la prophylaxie et/ou le retardement de l'apparition de la sclérose en plaques et de la maladie d'alzheimer
US12109271B2 (en) 2018-07-03 2024-10-08 University Of Florida Research Foundation, Incorporated Microparticle systems and their use for the treatment of multiple sclerosis
CA3181991A1 (fr) * 2020-06-22 2021-12-30 Iacob Mathiesen Methodes de traitement de la spasticite au moyen de compositions antispasmodiques et de la therapie par pression negative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334941A (en) * 1996-10-10 2000-11-24 Probe Internat Methods for treating infections using proteins which induce an immune response in one animal species but not in another
US20080193440A1 (en) * 2004-07-01 2008-08-14 Kobenhavns Universitet Method For Multiple Sclerosis Treatment and Prophylaxis By Treatment of Leptospira Infection
US8603978B2 (en) * 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150182A1 (fr) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions et procédés de traitement de l'anthrax
WO2008150181A1 (fr) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions et procédés de traitement des états pathologiques liés à l'exposition au charbon

Also Published As

Publication number Publication date
HK1167101A1 (en) 2013-02-01
US8389479B2 (en) 2013-03-05
SI2442832T1 (sl) 2014-12-31
IL216993A (en) 2016-03-31
SMT201400165B (it) 2015-01-15
US20100317589A1 (en) 2010-12-16
IL216993A0 (en) 2012-02-29
CN102458476B (zh) 2014-08-20
EP2442832A4 (fr) 2013-07-03
PT2442832E (pt) 2014-11-11
NZ577731A (en) 2010-08-27
EP2442832A1 (fr) 2012-04-25
DK2442832T3 (da) 2014-11-10
HRP20141035T1 (hr) 2014-12-19
BRPI1009606A2 (pt) 2016-10-11
WO2010147484A8 (fr) 2012-07-19
MX2011013661A (es) 2012-05-22
EP2442832B1 (fr) 2014-08-06
PL2442832T3 (pl) 2015-01-30
CN102458476A (zh) 2012-05-16
JP5646617B2 (ja) 2014-12-24
AU2010260585A8 (en) 2012-06-14
AU2010260585A1 (en) 2012-01-19
CA2688766C (fr) 2015-06-30
ES2521565T3 (es) 2014-11-12
CY1115714T1 (el) 2017-01-25
JP2012530132A (ja) 2012-11-29
AU2010260585B2 (en) 2013-02-21
CA2688766A1 (fr) 2010-12-16
WO2010147484A1 (fr) 2010-12-23

Similar Documents

Publication Publication Date Title
WO2010147484A8 (fr) Compositions et procédés pour le traitement de la sclérose en plaques
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
IN2012DN03883A (fr)
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
TN2010000060A1 (en) Proteasome inhibitors
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
IN2012DN00971A (fr)
JO2860B1 (en) Phenylendazolyl compounds
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2011007930A (es) Conjugados de insulina cristalina.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2011008179A (es) Peptidos para vacuna.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX336742B (es) Inhibidores de amida hidrolasa de acido graso.
EP2566485A4 (fr) Compositions immunostimulatrices et procédés d'utilisation de celles-ci
IN2014DN00254A (fr)
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2597949A4 (fr) Compositions submicroniques
MX2011010046A (es) Derivados de diaminopteridina.
PH12013500743A1 (en) Elastometric dental floss
GEP20146006B (en) Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3- dimethyl-butyramide
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5